NATALIE MUL: Open Payments
NPI 1588057160 · ENGLEWOOD, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,247 in 60 payments from 16 companies in 2025. Trend: 2023 $1,318 · 2024 $1,475 · 2025 $4,247
Food & beverage: $2,897Consulting: $1,350
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 7 | $1,939 |
| ABBVIE INC. | 15 | $760 |
| Ardelyx, Inc. | 6 | $197 |
| Novo Nordisk Inc | 3 | $195 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $179 |
| Aimmune Therapeutics, Inc. | 8 | $174 |
| Madrigal Pharmaceuticals | 2 | $163 |
| Mirum Pharmaceuticals, Inc. | 1 | $145 |
| Amgen Inc. | 1 | $132 |
| Lilly USA, LLC | 3 | $125 |
Products named: TREMFYA, SKYRIZI, RINVOQ, IBSRELA, ENTYVIO, REZDIFFRA, Livmarli, UPLIZNA.
Industry payments across CO — which companies pay providers there.
